Back to top
more

BioMarin Pharmaceutical (BMRN)

(Real Time Quote from BATS)

$69.42 USD

69.42
283,616

-0.68 (-0.97%)

Updated Oct 2, 2024 12:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 31% (77 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

BioMarin Begins Mid Stage Study on Gene Therapy Candidate

by Zacks Equity Research

BioMarin (BMRN) initiates a mid-stage study to evaluate its gene therapy candidate, valoctocogene roxaparvovec for treating in AAV5+ severe hemophilia A.

    Merck KGaA (MKGAF) Q1 Earnings and Revenues Decline Y/Y

    by Zacks Equity Research

    Merck KGaA (MKGAF) reports dismal first-quarter results with earnings declining year over year. Revenues fall due to continued negative currency movement.

      BioMarin (BMRN) Q1 Earnings Lower Than Expected, Sales Beat

      by Zacks Equity Research

      BioMarin (BMRN) reported mixed first-quarter results with earnings missing estimates but sales beating the same.

        What's in the Cards for BioMarin (BMRN) in Q1 Earnings?

        by Zacks Equity Research

        BioMarin (BMRN) is likely to see continued momentum in Kuvan and Vimizim sales. On the call, management is likely to comment on the launch preparation for pegvaliase.

          Catalyst Enrolls First Patient in Phase III Firdapse Study

          by Zacks Equity Research

          Catalyst (CPRX) enrolls the first patient in its phase III clinical trial (MSK-002) to evaluate the efficacy and safety of Firdapse in patients with MuSK antibody positive Myasthenia Gravis.

            The Zacks Analyst Blog Highlights: Agios Pharmaceuticals, BioMarin Pharmaceutical, Vertex Pharmaceuticals and Incyte

            by Zacks Equity Research

            The Zacks Analyst Blog Highlights: Agios Pharmaceuticals, BioMarin Pharmaceutical, Vertex Pharmaceuticals and Incyte

              Pfizer Starts Phase Ib for Duchenne Muscular Dystrophy Drug

              by Zacks Equity Research

              Pfizer (PFE) commences dosing in a phase Ib study, evaluating its gene therapy candidate, PF-06939926, for treating five to 12-yearold boys with duchenne muscular dystrophy.

                Gene Therapy in Limelight on Novartis Deal: 3 Stocks in Focus

                by Zacks Equity Research

                With the announcement of Novartis (NVS) acquiring AveXis, a clinical stage gene therapy company, several companies have started to develop the therapy with many of them having promising candidates in their pipelines.

                  Catalyst (CPRX) Up on New Drug Application for Firdapse

                  by Zacks Equity Research

                  Catalyst (CPRX) new drug application for its lead pipeline candidate keeps it on a growth trajectory.

                    BioMarin's MAA for Phenylketonuria Candidate Gains EU Nod

                    by Zacks Equity Research

                    BioMarin's (BMRN) MAA submission for its pipeline PKU candidate, pegvaliase, gets accepted in the EU. The same is under priority review in the United States with decision awaited this May.

                      BioMarin Pharmaceutical (BMRN) Down 3.1% Since Earnings Report: Can It Rebound?

                      by Zacks Equity Research

                      BioMarin Pharmaceutical (BMRN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

                        BioMarin (BMRN) Q4 Loss Wider Than Expected, Sales Beat

                        by Zacks Equity Research

                        BioMarin (BMRN) reports wider-than-expected loss in the fourth quarter of 2017 but beat estimates for sales on higher product revenues.

                          What to Expect From BioMarin (BMRN) This Earnings Season?

                          by Zacks Equity Research

                          BioMarin (BMRN) is likely to see continued momentum in Kuvan sales in Q4. On the call, management is likely to comment on Brineura's launch progress and on the launch preparation for pegvaliase.

                            Catalyst Gets Positive FDA Advise on Firdapse NDA Refiling

                            by Zacks Equity Research

                            Catalyst (CPRX) posts positive results from a recent Type C meeting with the FDA on resubmitting the new drug application for Firdapse in treating Lambert-Eaton myasthenic syndrome.

                              Arpita Dutt headshot

                              Vertex (VRTX) & Other Drug Stocks with FDA Catalysts this February

                              by Arpita Dutt

                              Here is a look at Vertex (VRTX) and a few other companies that await a decision from the FDA in February for label expansions or new drugs.

                                Surging Earnings Estimates Signal Good News for BioMarin Pharmaceutical (BMRN)

                                by Zacks Equity Research

                                BioMarin Pharmaceutical (BMRN) could be an interesting play for investors as it is seeing solid activity on the earnings estimate revision, along with decent short-term momentum.

                                  What Drives Catalyst Pharmaceuticals Above 250% This Year?

                                  by Zacks Equity Research

                                  We take a look at the factors that drive phenomenal growth in Catalyst Pharmaceuticals' (CPRX) share price in 2017.

                                    Arpita Dutt headshot

                                    Biotech Stock Roundup: BIIB, CELG Hit by Pipeline News, Acquisition Deals for Ignyta, Sucampo

                                    by Arpita Dutt

                                    A couple of acquisition agreements as well as pipeline news from Celgene (CELG) and Biogen were the key highlights this week in the biotech sector.

                                      BioMarin's (BMRN) Pegvaliase Review Period Extended by FDA

                                      by Zacks Equity Research

                                      BioMarin (BMRN) extended the review period of its biologics license application (BLA) for pegvaliase by three months to May 25, 2018.

                                        BioMarin's (BMRN) Gene Therapy Enters First Phase III Study

                                        by Zacks Equity Research

                                        BioMarin (BMRN) commences the first phase III study to evaluate the 6e13 vg/kg dose of its investigational gene therapy, valoctocogene roxaparvovec, for severe hemophilia A.

                                          Spark Therapeutics Stock Plunges on Hemophilia Therapy Data

                                          by Zacks Equity Research

                                          Spark Therapeutics (ONCE) plunged 35% as investors were not impressed by the data from a phase I/II study on its Hemophilia A candidate, SPK-8011.

                                            BioMarin Pharmaceutical (BMRN) Jumps: Stock Rises 7.5%

                                            by Zacks Equity Research

                                            BioMarin Pharmaceutical (BMRN) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.

                                              Here's Why Sarepta Stock is Up More Than 70% in 6 Months

                                              by Zacks Equity Research

                                              Sarepta's (SRPT) key product, Exondys 51, and lead pipeline candidate, golodirsen, have put up a good show in the past six months.

                                                Catalyst (CPRX) Reports Positive Phase III Data on Firdapse

                                                by Zacks Equity Research

                                                Catalyst (CPRX) reported encouraging top-line results from a phase III study for its pipeline candidate, Firdapse, for the treatment of Lambert-Eaton myasthenic syndrome.

                                                  Catalyst Initiates Phase II Study for Pipeline Drug Firdapse

                                                  by Zacks Equity Research

                                                  Catalyst (CPRX) announces the initiation of phase II study to evaluate safety, tolerability and efficacy of its lead pipeline candidate, Firdapse.